Pacific Edge has a plan to possibly launch a legal challenge if a determination to remove its hero product, bladder cancer diagnostic tool Cxbladder, from a list of tests approved for Medicare funding in the US is not changed.
The company gains most of its sales for the product in the US and said
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
